Musculo-Skeletal Market Research Reports

Musculoskeletal disorders (MSD) are conditions of muscles, related ligaments and other connective tissues and bones, which are majorly caused by over-use of weak muscles, tendons or ligaments. Recurrent pains, stiff and painful joints, swelling and dull aches, limited range of motion and cachexia are some of the major symptoms of MSDs. Some of the most common musculoskeletal disorders include rheumatoid arthritis, gout, Systemic Lupus Erythematosus (SLE), osteoporosis, osteoarthritis and septic arthritis.

Musculoskeletal disorders are the major cause of short-term and chronic disability. Treatment for MSDs may vary depending on severity of the condition. Generally, exercises along with some over-the-counter medicines are used to address occasional pains, however, advanced disorders may require physical and occupational therapies. Therapeutics such as corticosteroids, selective estrogen receptor modulators, parathyroid hormone, protein therapy, synthetic bone graft, ortho biologics, composite grafts, demineralized bone matrix, and Bone Morphogenetic Protein (BMPS) are also used for the treatment of advanced MSDs.

Biologic drugs with fewer side effects are emerging as a better alternative in musculoskeletal disorders

Major drugs used for MSD treatment are analgesics, anti-inflammatory drugs, immunosuppressives, muscle relaxants, corticosteroids and antipyretics. These medicines provide fair amount of relief but cause many side effects such as nausea, liver and kidney damage, acid-peptic disorders and irritation of the gastric tract. Patients are therefore shifting to biologic drugs that cause fewer side effects and provide better symptomatic relief for musculoskeletal diseases. This is a key reason behind increased number of biologic drugs being available in the market.